Capital International Sarl Has $2.92 Million Holdings in Grifols, S.A. (NASDAQ:GRFS)

Capital International Sarl boosted its stake in shares of Grifols, S.A. (NASDAQ:GRFS) by 12.5% in the 1st quarter, Holdings Channel.com reports. The firm owned 437,279 shares of the biotechnology company’s stock after buying an additional 48,455 shares during the quarter. Capital International Sarl’s holdings in Grifols were worth $2,921,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of the stock. Brandes Investment Partners LP increased its position in shares of Grifols by 22.2% during the 4th quarter. Brandes Investment Partners LP now owns 13,516,011 shares of the biotechnology company’s stock worth $156,245,000 after purchasing an additional 2,454,730 shares in the last quarter. Norges Bank acquired a new stake in shares of Grifols during the 4th quarter worth about $26,137,000. New York State Common Retirement Fund increased its position in shares of Grifols by 38.5% during the 4th quarter. New York State Common Retirement Fund now owns 2,058,286 shares of the biotechnology company’s stock worth $23,794,000 after purchasing an additional 572,439 shares in the last quarter. First Trust Advisors LP increased its position in shares of Grifols by 6.9% during the 4th quarter. First Trust Advisors LP now owns 4,684,749 shares of the biotechnology company’s stock worth $54,156,000 after purchasing an additional 302,380 shares in the last quarter. Finally, Anthracite Investment Company Inc. acquired a new stake in shares of Grifols during the 1st quarter worth about $1,970,000.

Grifols Trading Down 0.5 %

GRFS traded down $0.04 during midday trading on Friday, hitting $7.74. The company had a trading volume of 1,282,063 shares, compared to its average volume of 2,279,859. The company has a current ratio of 2.79, a quick ratio of 1.29 and a debt-to-equity ratio of 1.26. Grifols, S.A. has a twelve month low of $5.30 and a twelve month high of $12.15. The firm’s 50-day simple moving average is $7.38 and its 200-day simple moving average is $7.29.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.